Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis
Eli Muchtar(Mayo Clinic), Sameer A. Parikh(Mayo Clinic), Richard B. Kennedy(Mayo Clinic), Paul J. Hampel(Mayo Clinic), Jennifer A. Whitaker(Baylor College of Medicine), Myron J. Levin(Unknown), Timothy G. Call(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Susan L. Slager(Mayo Clinic), Heather C. Darby(Mayo Clinic), Wei Ding(Mayo Clinic), Kari G. Rabe(Mayo Clinic), Adriana Weinberg(University of Colorado Anschutz Medical Campus), Matthew Holets(Mayo Clinic in Florida), Congrong Miao(Centers for Disease Control and Prevention), D. Scott Schmid(Centers for Disease Control and Prevention), Yucai Wang(Mayo Clinic), Suzanne R. Hayman, Jennifer Canniff(University of Colorado Anschutz Medical Campus), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Michael Johnson(University of Colorado Anschutz Medical Campus)
Cited by 30
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
|Nature Genetics|1994|850
Recommendations for the Management of Herpes Zoster
|Clinical Infectious Diseases|2006|842
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735